tocilizumab

Teclistamab (Tecvayli®) is a first-in-class T-cell redirecting bispecific antibody that targets CD3 on the surface of T-cells and B-cell maturation antigen (BCMA) on plasma cells [1]. Teclistamab was approved by the FDA for patients with relapsed/refractory multiple myeloma (RRMM) after 4 lines...